Blue Helix Health, a company which was recently founded by Frode Marc Bohan, the co-founder of vitamin K2 supplier NattoPharma, has launched its first line of products designed to boost NAD+ levels through multiple mechanisms of action.
 
The company has also announced the launch of a research program which will attempt to uncover new compounds and mechanisms of action which can raise levels of NAD+, which is considered a marker of cellular aging and subject of intrigue among longevity researchers.
 
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme which plays a pivotal role in nutrient metabolism, protein activity enhancement, and the regulation of cellular aging. NAD+ levels diminish with age, which impairs mitochondrial function and overall cellular health. By the age of 70, it’s estimated that NAD+ levels are reduced by 80% compared to levels present in one’s 30s.
 
“At Blue Helix Health, we are at the forefront of NAD+ research, striving to uncover methods for producing NAD+ precursors, natural boosters, and conducting cutting-edge research into the mechanisms responsible for health benefits,” said Bohan.
 
The company’s new clinical research program will conduct human trials to evaluate the effects of supplementation on NAD+ levels, with a focus on downstream effects on cellular and neurological function, physical performance, mental acuity, metabolic function, and overall quality of life outcomes.
 
Research by the company so far has led to the development of novel production methods, advanced delivery technologies for active compounds, and the identification of new compounds targeting mechanisms for health improvements. The company is pursuing multiple patent applications while continually exploring new potential patent opportunities.

“We are very excited to introduce Blue Helix, a new business venture now bringing NAD+ precursors and boosters to North America,” said Ashish Suthar, PhD, managing director of the company. “Ultimately, we want to impact human health, helping people to live with vitality.”

Blue Helix’s new product offerings include patent-pending precursors that provide the essential building blocks for the endogenous production of NAD+, with a focus on derivatives of niacin. The second channel features plant-based products which stimulate NAD+ production, sourced from 900 candidate herbs through the company’s screening process to identify which compounds can best upregulate target sites for NAD+ production.
 
Blue Helix will be showcasing its products and research at booth 6573 at SupplySide West, from October 23-27 in Las Vegas, Nevada.